TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06224686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional dysphagia treatment
Description: Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, and low-frequency electrical stimulation of swallowing neuromusculature, etc., 30 min each time, once a day for 14 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional dysphagia treatment
Description: Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, and low-frequency electrical stimulation of swallowing neuromusculature, etc., 30 min each time, once a day for 14 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery based on action observation treatment
Description: First, the therapist explained the purpose and principle of the intervention method to the patient, keeping the surrounding environment quiet and comfortable to avoid the patient's mood fluctuations due to external interference. Then start the treatment, the video recorded in advance was given to the patient to watch, the playback device is a ipad. The content includes lip and tongue muscle relaxation exercises, healthy people eating, chewing, swallowing, drinking and other images. At the same time, the guidance was played, which was consistent with the content in the video. The video was played 3 times consecutively for 30 min each time, once a day for 14 days.
Study: NCT05675813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP+chidamide+tislelizumab
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T3 genetic subtype, for the remaining 5 cycles, they will receive tislelizumab 200mg d0 ivgtt and chidamide 20mg or 30mg biw (d1,4,8,11) by traditional 3+3 dose escalation methods and decide RP2D of chidamide.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T3 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.
Study: NCT06088745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Herpes Zoster Vaccine
Description: The active ingredient of the recombinant herpes zoster vaccine is varicella-zoster virus glycoprotein E fusion protein expressed in CHO cells by gene recombination technology. The LZ901 cell line carrying this gene is cultured in chemically defined medium. The harvest cell culture is purified by multi-step liquid chromatography. After Low pH incubation and virus removal filter package Nanofiltration inactivation/virus removal process, the bulk containing high-purity recombinant herpes zoster virus glycoprotein E is obtained. Finally, an alumina adjuvant is added to the formulated final product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Herpes Zoster Vaccine
Description: The active ingredient of the recombinant herpes zoster vaccine is varicella-zoster virus glycoprotein E fusion protein expressed in CHO cells by gene recombination technology. The LZ901 cell line carrying this gene is cultured in chemically defined medium. The harvest cell culture is purified by multi-step liquid chromatography. After Low pH incubation and virus removal filter package Nanofiltration inactivation/virus removal process, the bulk containing high-purity recombinant herpes zoster virus glycoprotein E is obtained. Finally, an alumina adjuvant is added to the formulated final product.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Herpes Zoster Vaccine Placebo
Description: Alumina adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Herpes Zoster Vaccine Placebo
Description: Alumina adjuvant
Study: NCT05675813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard CHOP
Description: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard CHOP
Description: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard CHOP
Description: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the 6 cycles.
Study: NCT05884489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A gamified smartphone app-based eating behaviour intervention
Description: All patients gained access to the healthy nutrition application and were encouraged to make full use of its feature, and they were also required to maintain a logbook through the application at home to follow-up on their diet. The intervention last for six weeks.
Study: NCT05125926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. The investigational are administered through Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. The investigational are administered through Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. The investigational are administered through Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. The investigational are administered through Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminum hydroxide

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminum hydroxide

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminum hydroxide

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminum hydroxide
Study: NCT05761340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Helfer skin tap injection technique
Description: 1. Place the patient in a seated position and open his right arm to inject into the deltoid muscle.~2. After determining the injection site, use the tips of the dominant hand fingers to hit the skin (about 15 strokes) for about five seconds to soften the muscles.~3. After cleaning the skin with alcohol, remove the syringe cover from the dominant hand. Make a V with the non-dominant hand and hit the skin three times.~4. During the third stroke, prick the syringe into the muscle at 90 degrees angle at the same time.~5. After aspiration, continue to hit the skin with the tips of the non-dominant hand fingers while injecting the drug with the dominant hand at a rate of 1 ml / 10 seconds.~6. After injecting the drug, make the non-dominant hand V-shaped and hit the skin three times, pulling the syringe needle out at the same time during the third stroke

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Injection technique
Description: 1. Place the patient in a seated position and open his right arm to inject into the deltoid muscle area.~2. After determining the injection site, prepare the skin with alcohol.~3. Grasp the skin with the thumb and index finger of the non-dominant hand and prick the syringe into the muscle at a 90-degree angle.~4. After aspiration, inject the drug with the dominant hand at a rate of 1 ml /10 seconds.~5. Remove the syringe needle 10 seconds after the drug is consumed
Study: NCT05722639

Intervention type: DEVICE
Intervention: X-Trodes acquisition system
Description: No intervention. The participants will sit passively while electrophysiology signals are captured from two devices in order to evaluate the signal quality.
Study: NCT05884775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool
Description: Once the program begins, the AI chatbot sends daily text messages that include the PRO questions; a link to a library of educational resources tailored to their responses and personalized motivational messages with support. Participants will also be sent links to the interactive web-based dashboard that visualizes their daily PRO and HbA1c data. PCPs will be able to view reports of patients' PRO and home A1c data through the EHR interface, which can be reviewed during visits with the patient or asynchronously to track patient PROs between visits.
Study: NCT05415800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Practice Facilitation Intervention
Description: The practice facilitation intervention (implementation strategy package) consists of QI projects designed for primary care providers with external practice facilitation and technical support provided by a QI Coach and Data Coach on our team.~The QI projects focus on the implementation of cancer prevention and early detection guidelines in primary care settings, specifically one QI project for each of the following clinical guidelines: colorectal cancer screening, lung cancer screening, and tobacco treatment. The study participants are the healthcare providers and staff, not the patients, since the goal of the practice facilitation intervention (implementation strategy package) is to improve the implementation of existing standard of care.
Study: NCT06295770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.
Study: NCT06076122

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement based on Salicornia extracts
Description: Freshly Salicornia ramosissima plants were recollected. Its aerial part were left to dry and hydroalcoholic extracts were produced by the company Extractos Vegetales S.A. (EVESA) (Cadiz, Spain \[https://evesa.com/\]). The Salicornia extracts were encapsulated by BIO-DIS laboratories (Seville, Spain \[https://www.bio-dis.com/\]), experts in food supplements and certified for such procedures.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules physically equal to the Salicornia extracts capsules
Study: NCT04721639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sphinx Yoga Therapy
Description: Sphinx Pose Yoga is among the best beginner Yoga Poses that relieve Lower Back Pain. It extends the back gently and activates muscles along the spine. The subject will be asked to lay down on their stomach with feet set hip-width apart, the elbows positioned under the shoulders, and the legs held together. The chin should be pointing towards the floor. Next, the subject is required to pull up the kneecaps, squeezing the thighs and buttocks, pressing the pubic bone into the floor and dropping shoulders back away from the neck and pushing the chest forward. In this position, the subject is asked to breathe and hold the pose for two to six breaths. By the end, the subject will be required to exhale, bringing the elbows to the sides and slowly lowering the chest and head to the floor.
Study: NCT04646811

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid valve
Description: Clip for the tricuspid valve implantation on top of best medical therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Best medical treatment
Description: Best medical therapy alone
Study: NCT05659303

Intervention type: PROCEDURE
Intervention: Laparoscopic hysterectomy
Description: Patient having undergone a hysterectomy, planned as an outpatient during the pre-operative consultation, by laparoscopic route.
Study: NCT04786405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Participants in the mindfulness meditation condition will practice a breath and body focused meditation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical hypnosis
Description: Participants in clinical hypnosis will be guided in a hypnosis practice with suggestions tailored towards shifting pain appraisals.
Study: NCT05302817

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyperpolarized xenon MRI
Description: Patients with non-small cell lung cancer scheduled for radiation therapy willing to take part in this study will undergo hyperpolarized xenon MRI at several time points prior and post RT. Images will be used to determine maps for functional lung avoidance and post-RT changes in the lung function and compared to standard-of-care assessment methods.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyperpolarized xenon MRI
Description: Patients with non-small cell lung cancer scheduled for radiation therapy willing to take part in this study will undergo hyperpolarized xenon MRI at several time points prior and post RT. Images will be used to determine maps for functional lung avoidance and post-RT changes in the lung function and compared to standard-of-care assessment methods.
Study: NCT06787040

Intervention type: OTHER
Intervention: Resource-Stratified Protocol
Description: The interventions are a set of protocols that accounts for varying levels of resources available at any given time for patients with severe traumatic brain injury across prehospital, ED, neurosurgery, and ICU. Protocols are available in the NIH-PMC website at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7055642/
Study: NCT06787066

Intervention type: DRUG
Group type: OTHER
Intervention: Propranolol Hydrochloride
Description: Examine how IV propranolol impacts sympathetic transduction

Intervention type: DRUG
Group type: OTHER
Intervention: Phentolamine Injection
Description: Examine how IV phentolamine impacts sympathetic transduction
Study: NCT06784622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Well-Root PT is clinically used in many areas such as pulp capping, perforation and resorption repair, root tip filling and apexification. As Well-Root PT is available in pre-mixed capsule form, it can provide a consistent and adequate consistency and clinical convenience. Well-Root PT can be applied directly into the oral cavity by placing the capsule in a syringe. In addition, Well-Root PT has a shorter setting time than MTA.Despite these advantages, there is no study in the literature on the effect of Well-Root PT on postoperative pain and tooth vitality after pulpotomy in mature permanent molars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Well-Root PT is clinically used in many areas such as pulp capping, perforation and resorption repair, root tip filling and apexification. As Well-Root PT is available in pre-mixed capsule form, it can provide a consistent and adequate consistency and clinical convenience. Well-Root PT can be applied directly into the oral cavity by placing the capsule in a syringe. In addition, Well-Root PT has a shorter setting time than MTA.Despite these advantages, there is no study in the literature on the effect of Well-Root PT on postoperative pain and tooth vitality after pulpotomy in mature permanent molars
Study: NCT06782763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation device
Description: Activating neurons: rTMS can activate or inhibit neuronal activity in certain brain areas, changing the activity pattern of neural networks. Neuroplasticity: By changing the strength and connection mode of synapses, it promotes the plasticity of the nervous system, which helps treat neuropsychiatric diseases. Regulating neurotransmitters: rTMS can regulate the release of neurotransmitters, affect nerve conduction, and thus improve disease symptoms.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation device
Description: Activating neurons: rTMS can activate or inhibit neuronal activity in certain brain areas, changing the activity pattern of neural networks. Neuroplasticity: By changing the strength and connection mode of synapses, it promotes the plasticity of the nervous system, which helps treat neuropsychiatric diseases. Regulating neurotransmitters: rTMS can regulate the release of neurotransmitters, affect nerve conduction, and thus improve disease symptoms.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation device
Description: Activating neurons: rTMS can activate or inhibit neuronal activity in certain brain areas, changing the activity pattern of neural networks. Neuroplasticity: By changing the strength and connection mode of synapses, it promotes the plasticity of the nervous system, which helps treat neuropsychiatric diseases. Regulating neurotransmitters: rTMS can regulate the release of neurotransmitters, affect nerve conduction, and thus improve disease symptoms.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation device
Description: Activating neurons: rTMS can activate or inhibit neuronal activity in certain brain areas, changing the activity pattern of neural networks. Neuroplasticity: By changing the strength and connection mode of synapses, it promotes the plasticity of the nervous system, which helps treat neuropsychiatric diseases. Regulating neurotransmitters: rTMS can regulate the release of neurotransmitters, affect nerve conduction, and thus improve disease symptoms.
Study: NCT05470595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
Study: NCT05971940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06786416

Intervention type: OTHER
Intervention: PEQUOD
Description: During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.
Study: NCT06786117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLP swallowing exercises
Description: Clinical speech language pathologists will provide standard exercises based on the abnormalities seen on the modified barium swallow. Exercises are expected to include the effortful swallow, the Mendelsohn maneuver, expiratory muscle strength training with the EMST-150, supraglottic swallow, super supraglottic swallow, chin tuck against resistance isokinetic exercise, chin tuck against resistance isometric exercise, Masako maneuver, Shaker isometric head lift exercise, Shaker isokinetic head lift exercise, Falsetto high pitch glide exercise, tongue press exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLP swallowing exercises
Description: Clinical speech language pathologists will provide standard exercises based on the abnormalities seen on the modified barium swallow. Exercises are expected to include the effortful swallow, the Mendelsohn maneuver, expiratory muscle strength training with the EMST-150, supraglottic swallow, super supraglottic swallow, chin tuck against resistance isokinetic exercise, chin tuck against resistance isometric exercise, Masako maneuver, Shaker isometric head lift exercise, Shaker isokinetic head lift exercise, Falsetto high pitch glide exercise, tongue press exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofunctional exercises
Description: Participants will get a variety of exercises aimed at improving bolus formation, strengthening the seal of the soft palate with the tongue, and habituating nasal breathing. There will also be exercises aimed at stabilizing the epiglottis and strengthening the muscles supporting the lateral pharyngeal walls. Expiratory muscle strength training with the EMST-150 will also be done.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofunctional exercises
Description: Participants will get a variety of exercises aimed at improving bolus formation, strengthening the seal of the soft palate with the tongue, and habituating nasal breathing. There will also be exercises aimed at stabilizing the epiglottis and strengthening the muscles supporting the lateral pharyngeal walls. Expiratory muscle strength training with the EMST-150 will also be done.
Study: NCT06787313

Intervention type: OTHER
Intervention: precision palliative care
Description: Participants receive precision palliative care based on scale screening result.
Study: NCT06784271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylcapsaicin
Description: 2.5mg of Phenylcapsaicin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06788145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support Single-Session Intervention
Description: Single-session intervention to increase self-efficacy, social support, help-seeking, and recovery-oriented behaviors to address disordered eating.
Study: NCT06785454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorundrostat
Description: Lorundrostat tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorundrostat
Description: Lorundrostat tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lorundrostat matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lorundrostat matching placebo tablet.